ライフサイエンスコーパス: curative treatment

1 crine disorder for which surgery is the only curative treatment.

2 ents with localized PC, candidates for local curative treatment.

3 Overall, 23% of cases received potentially curative treatment.

4 er (CRC) is common, with surgery as the main curative treatment.

5 more and novel opportunities for potentially curative treatment.

6 plications and growth, other admissions, and curative treatment.

7 the ability to translate this method into a curative treatment.

8 other clinicopathologic factors and type of curative treatment.

9 en the patient eligibility for what may be a curative treatment.

10 ovides more persons with the opportunity for curative treatment.

11 cular therapy should shorten the duration of curative treatment.

12 surgery remains the mainstay of potentially curative treatment.

13 or such patients may decrease the chances of curative treatment.

14 er number of patients will benefit from this curative treatment.

15 use of morbidity and mortality, even despite curative treatment.

16 ized populations less likely to benefit from curative treatment.

17 mmon, lethal complication of RDEB that lacks curative treatment.

18 ediatric brain tumors in desperate need of a curative treatment.

19 ciated with the ability to offer potentially curative treatment.

20 (MS) is a chronic autoimmune disease with no curative treatment.

21 urodegenerative dementias, with no available curative treatment.

22 that has several therapeutic options but no curative treatment.

23 than did those who were further in time from curative treatment.

24 hypopharynx, or larynx undergoing first-line curative treatment.

25 does not appear to be a contraindication to curative treatment.

26 ed patients who stand to benefit most from a curative treatment.

27 mber of days from diagnosis to initiation of curative treatment.

28 ses such as multiple sclerosis, which has no curative treatment.

29 ognoses, limited therapeutic options, and no curative treatment.

30 ed patients with a non-ICU policy or with no curative treatment.

31 ong working age adults and does not have any curative treatments.

32 and with metastatic cancer not receiving any curative treatments.

33 for the development of preventative and even curative treatments.

34 ing the past 20 y, but we are still far from curative treatments.

35 A total of 1195 patients (34.7%) received curative treatment, 1374 (39.9%) received noncurative tr

36 00 men per year), and 108% more men received curative treatment (152 vs 73 [95% CI: 66-85] per 100 00

37 years shows that, without primaquine radical curative treatment, 3 in 4 patients relapse.

38 Curative treatment 6 weeks post-infection resulted in su

39 3%-14.0%) and a 6.8% increased likelihood of curative treatment (95% CI, 2.8%-11.0%).

40 Improved testing and linkage could increase curative treatment access.

41 h patients were less frequently allocated to curative treatment (adenocarcinoma: OR=0.31, 95%CI 0.26-

42 ourteen of 44 (32%) participants underwent a curative treatment after TACE.

43 m earlier diagnosis and access to first-line curative treatments, among which RFA provided the best v

44 ependent predictor of tumor recurrence after curative treatment and all-cause mortality in patients w

45 on was partly explained by stratification by curative treatment and further adjustment for diagnosis

46 hemotherapy was allowed) and not amenable to curative treatment and had an Eastern Cooperative Oncolo

47 Discussing no further curative treatment and hospice was reported as most diff

48 The probability of patients receiving curative treatment and long-term survival increased from

49 Its recognition is critical because curative treatment and prognosis require early diagnosis

50 to a higher probability of benefiting from a curative treatment and so a higher survival probability.

51 life expectancy in patients who had received curative treatment and whose hypercortisolism remained i

52 th patients in prison less likely to receive curative treatments and having lower overall survival th

53 (CRC) patients to determine the appropriate curative treatments and post-surveillance screening for

54 with only one third of patients eligible for curative treatments and very limited survival benefits w

55 Eleven participants (50%) underwent curative treatment, and 11 (50%) noncurative treatment.T

56 n received primary endocrine therapy, 26 432 curative treatment, and 19 526 surveillance.

57 patients with PC received primary ET, 26,432 curative treatment, and 19,527 surveillance.

58 esection is regarded as the only potentially curative treatment, and adjuvant chemotherapy with gemci

59 There is no curative treatment, and current strategies proposed for

60 ate-lowering therapy, which is a definitive, curative treatment, and fewer than a half of patients ad

61 ow-risk cancers are referred for unnecessary curative treatment, and much treatment is given at low-v

62 nclude immediate curative treatment, delayed curative treatment, and no treatment, with additional co

63 95% CI, 1.11 to 1.30] for men undergoing ET, curative treatment, and surveillance, respectively).

64 nefits, defined as early tumor detection and curative treatment, and surveillance-related physical ha

65 transplantation (SCT) is well accepted as a curative treatment approach for younger patients with my

66 may revert abnormal LSC function and support curative treatment approaches in this malignancy.

67 d HRQL, surveillance protocols after primary curative treatment are varied and inconsistent, reflecti

68 is affecting 16% of population globally), no curative treatments are available because of the limited

69 mplications are difficult to diagnose and no curative treatments are available.

70 children, yet no human vaccine nor efficient curative treatments are available.

71 ressive and debilitating condition for which curative treatments are currently unavailable.

72 a radical treatment for prostate cancer, but curative treatments are elusive for poorly differentiate

73 of patients diagnosed at early stages, when curative treatments are feasible.

74 The only curative treatments are surgical resection or liver tran

75 rogeneity is critical for the development of curative treatments as the failure to eliminate therapy-

76 l lymphotropic virus type-I (HTLV-I) without curative treatment at present.

77 ling hallmark of chronic lung disease, lacks curative treatments at present.

78 lantation (alloHSCT) is the only potentially curative treatment available for patients with B-cell ch

79 sease suppression is still required, with no curative treatment available to date.

80 odegenerative disease, and with no efficient curative treatment available, its medical, social, and e

81 ood tumor of the brainstem with currently no curative treatment available.

82 ransplantation and gene therapy are the only curative treatments available, and the best-known progno

83 DS patients are not eligible for potentially curative treatment because of advanced age and/or clinic

84 fatal, Pancoast tumours are now amenable to curative treatment because of improvements in combined m

85 y GVHD, limiting the use of this potentially curative treatment beyond malignant disorders.

86 tem-cell transplantation (HSCT) represents a curative treatment but is limited by donor availability,

87 Tumor resection remains the only curative treatment but is often not possible because of

88 patients who have cancer, who have completed curative treatment, but who remain at high risk for recu

89 tic hepatocellular carcinoma not amenable to curative treatment, but with tumours amenable to TACE, E

90 ly recommended and an extended indication of curative treatment by HSCT should be considered.

91 unction at HCC diagnosis and better OS after curative treatment compared to counterparts with HCV and

92 is a pressing public health problem with no curative treatment currently available.

93 adiation treatment options include immediate curative treatment, delayed curative treatment, and no t

94 patients within Milan criteria submitted to curative treatments did not show any difference in survi

95 hese patients undergo palliative rather than curative treatment due to dissemination of cancer along

96 nd pharmacodynamic models more predictive of curative treatment durations are set forth.

97 ilar patterns were seen for men who received curative treatment (DVT: 1.73, 1.47-2.01; pulmonary embo

98 Efforts are needed to optimize curative treatment effectiveness among patients with ear

99 No curative treatment except for radical surgery (almost ne

100 gnostic tools for early detection nor does a curative treatment exist.

101 However, no curative treatments exist, suggesting that novel approac

102 ctory to available therapies or for which no curative treatments existed.

103 mmon heritable hematological disease, yet no curative treatment exists for this disorder.

104 ansplantation (HCT) represents a potentially curative treatment for a variety of hematologic malignan

105 SCT) is, in many clinical settings, the only curative treatment for acute myeloid leukemia (AML).

106 PEG-ADA) has proved a life-saving though non-curative treatment for ADA-SCID patients.

107 pecimens from 116 patients who had undergone curative treatment for adenocarcinoma of the colon.

108 oietic stem cell transplantation (HSCT) is a curative treatment for advanced hematologic malignancies

109 Since there is no curative treatment for advanced prostate cancer, explora

110 Allergen immunotherapy (AIT) is the only curative treatment for allergy.

111 end the capability of delivering potentially curative treatment for bilateral hepatic colorectal meta

112 arrow transplantation (BMT) is a potentially curative treatment for both inherited and acquired disea

113 w stem cell transplantation is a potentially curative treatment for both malignant and nonmalignant d

114 c stem cell transplantation (allo-HSCT) is a curative treatment for both malignant and nonmalignant h

115 otodynamic therapy is an effective and often curative treatment for certain solid tumors.

116 oietic stem cell transplantation (HSCT) is a curative treatment for CGD, particularly effective when

117 for HBV therapeutic vaccination.IMPORTANCE A curative treatment for chronic hepatitis B must eliminat

118 n increasingly used therapeutic strategy for curative treatment for colorectal metastases.

119 There is still no curative treatment for Duchenne muscular dystrophy (DMD)

120 Liver transplantation (LT) is the best curative treatment for early hepatocellular carcinoma (H

121 powered trials demonstrating the benefit of curative treatment for early-stage prostate cancer.

122 t the efficacy of gene transfer therapy as a curative treatment for Gaucher disease.

123 Patients who underwent curative treatment for HCC and recovered within 6 wk wer

124 Curative treatment for HCC resulted the only independent

125 ecting the combination of the opioid crisis, curative treatment for HCV infection, and mortality amon

126 transplantation (allo-HCT) is a potentially curative treatment for hematologic and immunologic disea

127 opoietic cell transplantation (HCT) can be a curative treatment for hematologic malignancies and over

128 eic stem cell transplantation (alloSCT) is a curative treatment for hematological malignancies.

129 cquired liver diseases and could represent a curative treatment for hemophilia A.

130 Despite the availability of curative treatment for hepatitis C virus (HCV) infection

131 y patients who, after undergoing potentially curative treatment for hepatocellular carcinoma, are at

132 Allogeneic bone marrow transplantation is a curative treatment for leukemia and lymphoma, but graft-

133 revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while ther

134 Esophagectomy is an important, potentially curative treatment for localized esophageal cancer, but

135 atopoietic cell transplantation (HCT) can be curative treatment for lymphoid malignancies, but it has

136 Bone marrow transplantation is a curative treatment for many diseases, including leukemia

137 oietic stem cell transplantation is the only curative treatment for many malignant hematologic diseas

138 ection represents the best and a potentially curative treatment for metastatic colorectal cancer to t

139 oietic stem cell transplantation (HSCT) is a curative treatment for multiple disorders, but deficienc

140 c stem cell transplantation remains the only curative treatment for myelodysplastic syndrome.

141 oietic stem-cell transplantation is the only curative treatment for myelofibrosis.

142 on of autoimmune conditions, but there is no curative treatment for neurodegenerative conditions.

143 Surgical resection is the only curative treatment for pancreatic and periampullary canc

144 cell transplantation (HSCT) is a potentially curative treatment for patients affected by Wiskott-Aldr

145 Curative treatment for patients with advanced head and n

146 The standard curative treatment for patients with esophageal cancer i

147 cell transplantation (HSCT) remains the only curative treatment for patients with Fanconi anemia (FA)

148 transplantation (alloHSCT) is a potentially curative treatment for patients with high-risk acute leu

149 myeloablative conditioning is the preferred curative treatment for patients with high-risk blood can

150 cell transplantation is the only potentially curative treatment for patients with myelodysplastic syn

151 ansplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syn

152 the Whipple procedure) is the only potential curative treatment for periampullary tumours.

153 Mr A needs surgery for potentially curative treatment for presumed colon cancer, but he is

154 Treatment selection for men undergoing curative treatment for prostate cancer is often a challe

155 anscription, suggesting that even apparently curative treatment for PTB may not eradicate all of the

156 itor cells (HSPCs) may potentially provide a curative treatment for SCD.

157 Liver transplantation (LT) represents a curative treatment for small hepatocellular carcinoma (H

158 lantation (allo-HCT) remains the backbone of curative treatment for the majority of fit adults diagno

159 cell transplantation (HCT) remains the only curative treatment for this condition, but transplant su

160 There is currently no curative treatment for this disorder.

161 Allergen-specific immunotherapy is the only curative treatment for type I allergy.

162 stem cell (HSC) transplantation represents a curative treatment for various hematological disorders.

163 Surgery is the most effective curative treatment for various tumour types.

164 Curative treatments for ADHD do not exist but evidence-b

165 cancer is now favorable, there are still no curative treatments for castration-resistant prostate ca

166 Surgery and radiation continue to be curative treatments for localized disease but have adver

167 Resistance to therapy and lack of curative treatments for metastatic breast cancer suggest

168 liver transplantation (CLT) are potentially curative treatments for patients with hepatocellular car

169 (HSCT) and gene therapy (GT) are potentially curative treatments for severe combined immunodeficiency

170 Currently, curative treatments for SMS do not exist.

171 olid tumors and thus a therapeutic target in curative treatments for solid cancers.

172 successful remission; however, there are no curative treatments for tumors that have progressed beyo

173 ase-free adult OPSCC survivors who completed curative treatment from January 1, 2000, to December 31,

174 h Administration (population enriched with 3 curative treatments) from 2008 to 2016.

175 Patients were stratified by curative treatment, geography, Child-Pugh status, and re

176 f this approach is relatively modest, and no curative treatment has been identified.

177 he subset that received guideline-concordant curative treatment (hazard ratio, 2.63; 95% CI, 1.05 to

178 p < 0.001), and a decreased eligibility for curative treatment (HBV-14%, HCV-34%; p < 0.05).

179 ], 0.4; 95% CI, 0.2-0.9; P = 0.04), previous curative treatments (HR, 0.3; 95% CI, 0.2-0.7; P = 0.003

180 c T cell response may also be required after curative treatment if residual latently infected cells r

181 ulfilled Milan criteria in 79.3%, leading to curative treatment in 70.4%.

182 transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiecta

183 o might benefit from novel therapies or even curative treatment in the form of hematopoietic cell tra

184 The group most likely to receive curative treatment in the SEER-Medicare cases was patien

185 transplantation remains the only potentially curative treatment in this disorder, but many recent stu

186 Socioeconomic factors affect selection of curative treatments in HL.

187 sed with early disease over time, the use of curative treatments in this patient group has recently p

188 cm) primary and metastatic liver tumors with curative treatment intent.

189 ng breast cancer care from diagnosis through curative treatment into survivorship, and metastatic dis

190 Despite decades of research no curative treatment is available and it thus remains asso

191 Currently, no curative treatment is available for early-to-intermediat

192 ly leads to end-stage kidney disease, and no curative treatment is available.

193 nce of chronic pancreatitis is rising and no curative treatment is available.

194 Currently, no curative treatment is available.

195 Currently, the only curative treatment is hematopoietic stem cell transplant

196 Curative treatment is limited to allogeneic hematopoieti

197 cause most patients are diagnosed late, when curative treatment is not possible.

198 The only potentially curative treatment is the surgical resection of the prim

199 Curative treatment is then initiated at the first sign o

200 anges over time for those who survived since curative treatment is unknown.

201 nfection (CHB), and the development of novel curative treatments is urgently needed.

202 neurodegenerative disease, currently without curative treatment, is associated with the accumulation

203 hich has an unknown pathogenesis and lacks a curative treatment, is becoming more prevalent.

204 reatment course including current first-line curative treatment: liver resection, radiofrequency abla

205 dverse event with no current preventative or curative treatment measures.

206 nd transplantation has become one of the few curative treatment modalities for patients with HCC, esp

207 ymptomatic nature of the disease and lack of curative treatment modalities, the 5-y survival rate of

208 les aged 18 years or older who had completed curative treatment more than 3 months before enrollment

209 In spite of great advances in the design of curative treatments, most patients currently receive pal

210 In the absence of curative treatment, multidisciplinary care is targeted t

211 ocellular carcinoma that was not amenable to curative treatment; no previous systemic treatment; and

212 and included patients who were eligible for curative treatment of a primary squamous cell carcinoma

213 e first patient received RF ablation for the curative treatment of a solitary residual hepatic mass f

214 ntation (allo-HCT) is currently the standard curative treatment of acute leukemia, relapse remains un

215 Despite advances in the curative treatment of acute myeloid leukemia (AML), recu

216 Curative treatment of aggressive Kaposi sarcoma (KS) wit

217 hematopoietic stem cell transplantation as a curative treatment of chronic myeloid leukemia (CML).

218 cessible with endoscopy, early diagnosis and curative treatment of esophageal cancer is possible.

219 cell transplantation (HSCT) remains the only curative treatment of FA patients with MDS or AML.

220 ould reduce the risk of HCC recurrence after curative treatment of HBV-related HCC.

221 From 2000 to 2010, 303 patients underwent curative treatment of HCC; 52 (17.2%) and 162 (53.5%) pa

222 The prevention of tumor recurrence after curative treatment of hepatocellular carcinoma (HCC) is

223 ic resonance (MR) imaging on eligibility for curative treatment of hepatocellular carcinoma (HCC).

224 transplantation is effective and potentially curative treatment of hereditary fibrinogen amyloidosis.

225 Tumor resistance to current drugs prevents curative treatment of human colon cancer.

226 Curative treatment of intrahepatic cholangiocarcinoma (I

227 The curative treatment of locally advanced head and neck squ

228 on margins (CRM) are the cornerstone for the curative treatment of locally advanced rectal cancer (LA

229 een successfully integrated into potentially curative treatment of locally advanced squamous-cell car

230 y (CRT) is an alternative to surgery for the curative treatment of oesophageal carcinoma.

231 s remains one of the major challenges in the curative treatment of patients with cancer.

232 While R0 resection remains the mainstay of curative treatment of patients with GEJ cancer, the opti

233 After curative treatment of patients with HCC, one 2,200-MBq d

234 transplantation (allo-HSCT) is a potentially curative treatment of patients with nonmalignant or mali

235 ne and tafenoquine) are used for the radical curative treatment of Plasmodium vivax malaria and can c

236 Clinical outcomes after curative treatment of resectable pancreatic ductal adeno

237 stem cell transplantation (HSCT) is the only curative treatment of severe congenital neutropenia (SCN

238 rove to be the final frontier in the optimal curative treatment of these disorders.

239 nsplantation is hampered in its success as a curative treatment of type 1 diabetes by the absence of

240 far proved effective both for preventive and curative treatments of AMR in sensitized patients and pa

241 cell transplantation (allo-SCT) is the only curative treatment option for a number of hematologic ma

242 -marrow transplantation (BMT) has provided a curative treatment option for chronic myeloid leukaemia

243 Currently, salvage RP represents the only curative treatment option for these patients.

244 Radiotherapy is a curative treatment option in prostate cancer.

245 or combination therapy has failed to offer a curative treatment option, most likely because these pat

246 clide therapy (PRRT), these patients have no curative treatment option.

247 antation (HSCT) remains the only potentially curative treatment option.

248 ent brentuximab vedotin may be a potentially curative treatment option.

249 Novel disease biomarkers and curative treatment options are strongly needed.

250 itor crizotinib in patients who had no known curative treatment options at diagnosis or with relapsed

251 umors to become surgical candidates, provide curative treatment options in nonsurgical candidates, or

252 Because of the lack of curative treatment options, interferons (IFN) have been

253 on and liver transplantation remain the only curative treatment options.

254 n indolent cancer, with effective but rarely curative treatment options.

255 sk in 76,600 patients with PC undergoing ET, curative treatment, or surveillance.

256 ncer who were receiving endocrine treatment, curative treatment, or surveillance.

257 After radical curative treatment, participants were randomly assigned

258 ffective than benznidazole and nifurtimox as curative treatments, particularly for acute stage infect

259 With no curative treatments presently available, retrovirally tr

260 (odds ratio [OR] 2.08, 95% CI 1.80-2.37) and curative treatment rates (OR 2.24, 95% CI 1.99-2.52).

261 ported rates of early stage tumor detection, curative treatment receipt, or survival, stratified by H

262 esophagectomy appears to remain the optimum curative treatment regime in patients with locoregional

263 neous T-cell lymphoma (CTCL) are limited and curative treatment regimens are not available.

264 al molecules that may one day become part of curative treatment regimens for chronic hepatitis B.

265 he availability of effective diagnostics and curative treatment regimens for tuberculosis, millions o

266 considering allogeneic transplantation as a curative treatment relative to other available contempor

267 nts who were receiving or recently completed curative treatment reported more symptoms and better sym

268 as a result of rising incidence and limited curative treatment(s) for patients with advanced disease

269 III clinical trial design has lagged in the curative treatment setting, particularly in combination

270 antiretroviral therapy following potentially curative treatment strategies.

271 of alternative, synergistic, and potentially curative treatment strategies.

272 n oesophageal cancer that was unsuitable for curative treatment, symptomatic dysphagia, Eastern Coope

273 gnosed in prison were less likely to undergo curative treatment than matched patients in the general

274 or cell (HSPC) gene therapy is a potentially curative treatment that represents an alternative to all

275 In the absence of curative treatment, the management of pre-eclampsia invo

276 After a median follow-up of 50 months after curative treatment, the most frequent cause of death was

277 However, given the lack of a curative treatment, the prognosis of NMO remains poor in

278 ection in humans, and there is no recognized curative treatment to clear tissue cysts.

279 s, it is becoming possible to offer targeted curative treatments to more and more patients.

280 umor size, count, and receipt of potentially curative treatments (transplantation, resection, and abl

281 Currently, curative treatment trials for Alzheimer's disease (AD) h

282 Curative treatment was associated with reduced HCC-relat

283 d patient prognosis regarded as poor because curative treatment was only available for very few leuko

284 Of over 19 patients identified with E-GISTs, curative treatment was surgical for 16 patients, with en

285 At multivariate analysis, HCC curative treatment was the only independent predictor (H

286 ase but not to be candidates for potentially curative treatment were compared (1992-2002).

287 y to therapy and for whom there was no known curative treatment were eligible.

288 ollow-up of less than 5 years since the last curative treatment were excluded from the analysis.

289 Early-stage HCC at diagnosis and curative treatment were secondary outcomes assessed usin

290 ave advanced disease that is not amenable to curative treatment, which means that they are likely to

291 As a result, the search for curative treatments, which are sorely lacking in the hea

292 ell transplantation (HSCT) was found to be a curative treatment with a relatively good prognosis beca

293 Curative treatment with DAA attenuated the liver stiffne

294 In addition, we tested the efficacies of curative treatments with either the MIF antagonist ISO-1

295 and gene therapy continue to be evaluated as curative treatments with increasing success rates for so

296 Finally, we found that curative treatments with the MIF antagonist ISO-1 or ant

297 l resection is currently considered the only curative treatment, with only about 25% of patients bein

298 em cell (HSC) transplantation represents the curative treatment, with thalassemia-free survival excee

299 lower dose than required to achieve the same curative treatment without MDNPs.

300 C virus (HCV) is the first step to accessing curative treatment, yet many infected adults in the Unit